tiprankstipranks
Trending News
More News >
Fevertree Drinks (GB:FEVR)
LSE:FEVR
Advertisement

Fevertree Drinks (FEVR) AI Stock Analysis

Compare
101 Followers

Top Page

GB:FEVR

Fevertree Drinks

(LSE:FEVR)

Select Model
Select Model
Select Model
Neutral 69 (OpenAI - 4o)
Rating:69Neutral
Price Target:
942.00p
▲(15.58% Upside)
Fevertree Drinks' overall stock score is driven by its strong financial performance, characterized by consistent revenue growth and robust cash flow management. However, the high P/E ratio suggests a premium valuation, which, combined with neutral technical indicators, tempers the overall score.
Positive Factors
Negative Factors

Fevertree Drinks (FEVR) vs. iShares MSCI United Kingdom ETF (EWC)

Fevertree Drinks Business Overview & Revenue Model

Company DescriptionFevertree Drinks Plc, together with its subsidiaries, develops and supplies premium mixer drinks in the United Kingdom, the United States, Europe, and internationally. The company's products include Indian tonic water, Mediterranean tonic water, elderflower tonic water, Clementine tonic water, ginger beer, ginger ale, and cola distillers. It sells its products under Fever-Tree brand name to pubs, bars, and restaurants. The company was formerly known as Fevertree Topco Limited and changed its name to Fevertree Drinks Plc in October 2014. Fevertree Drinks Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
How the Company Makes MoneyFevertree Drinks generates revenue primarily through the sale of its premium mixers to both retail and wholesale customers. The company benefits from a growing trend of consumers seeking high-quality mixers to enhance their drinking experience, particularly in the cocktail and spirits sector. Key revenue streams include direct sales to supermarkets, specialty retailers, and distribution agreements with bars and restaurants. Additionally, Fevertree has established significant partnerships with major beverage brands and distributors, which help expand its market reach and enhance brand visibility. The company's focus on innovation and product development, along with its marketing strategies, contributes to its strong financial performance.

Fevertree Drinks Earnings Call Summary

Earnings Call Date:Sep 11, 2025
(Q2-2024)
|
% Change Since: |
Next Earnings Date:Mar 12, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong performance in the U.S. market, significant EBITDA and gross margin improvements, and robust growth in non-tonic products. However, challenges remain in the UK and European markets, with revenue declines and on-trade channel difficulties noted. Despite these challenges, the company is optimistic about future growth opportunities.
Q2-2024 Updates
Positive Updates
Significant EBITDA Growth
Fevertree delivered almost 80% EBITDA growth, indicating strong margin recovery.
U.S. Market Performance
The brand delivered double-digit growth at constant currency in the U.S., outpacing the total mix of category by about 10%.
Gross Margin Improvement
Improved gross margin by 520 basis points year-on-year during H1, with an expectation of 600 basis points improvement across the full year.
Rest of the World Growth
Delivered a 56% increase in revenue year-on-year in the Rest of the World region, with strong performance in Canada and Australia.
Non-Tonic Product Growth
Non-tonic products have grown by 24% CAGR over the last 6 years, now making up 40% of sales.
Negative Updates
Decline in UK Revenue
UK revenue declined by 6% year-on-year, primarily due to the challenging on-trade backdrop and continued weakness of the gin category.
Europe Revenue Decline
Revenue in Europe declined by 10% at constant currency, impacted by subdued consumer confidence and poor weather.
Challenges in On-Trade Channel
On-Trade channel remains challenging, compounded by poor weather in June, affecting performance in key markets.
Company Guidance
During the Fevertree Q2 2024 earnings call, the company provided guidance indicating strong financial performance despite challenging market conditions. The executives highlighted an impressive 80% growth in EBITDA and a 520 basis point improvement in gross margin during the first half, with a commitment to achieve 600 basis points for the full year. Revenue growth was reported at 2% on a constant currency basis, with the U.S. market showing double-digit growth and outpacing the total mixer category by 10%. In the U.K., Fevertree maintained its position as the number one brand by value, although it faced challenges in the on-trade sector due to poor weather. The European market saw a 10% decline at constant currency, impacted by weather and order phasing, but underlying brand revenue increased by 1% year-on-year. The Rest of the World region experienced a 56% revenue increase, driven by strong performance in Australia and Canada. Looking ahead, Fevertree anticipates revenue growth acceleration and continued margin recovery, with expectations to deliver a further 200 basis point gross margin improvement in 2025, despite ongoing macroeconomic challenges.

Fevertree Drinks Financial Statement Overview

Summary
Fevertree Drinks exhibits strong financial health with consistent revenue growth, robust cash flow, and a solid balance sheet. The company maintains low debt levels and high equity, supporting stability and growth. While margins are strong, improving net profit margins could enhance performance further.
Income Statement
78
Positive
Fevertree Drinks has shown consistent revenue growth over the years, with a notable increase from 2023 to 2024. The gross profit margin and EBIT margin remain solid, indicating effective cost management. However, the net profit margin is relatively moderate due to industry competition. The company's strong EBITDA margin highlights operational efficiency.
Balance Sheet
82
Very Positive
The company maintains a robust balance sheet with a healthy equity ratio. Fevertree Drinks has low debt levels, resulting in a favorable debt-to-equity ratio. The return on equity is strong, reflecting effective use of shareholders' funds. However, the company's asset base growth is moderate, suggesting a focus on maintaining financial stability.
Cash Flow
85
Very Positive
Fevertree Drinks demonstrates a strong cash flow position, with significant free cash flow growth from 2023 to 2024. The operating cash flow to net income ratio indicates efficient cash generation relative to profits. The free cash flow to net income ratio is also robust, underscoring the company's ability to generate cash beyond its net earnings.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue339.90M368.50M364.40M344.30M311.10M252.10M
Gross Profit121.80M138.40M109.00M118.80M130.90M116.30M
EBITDA43.00M45.70M30.80M37.20M60.60M55.60M
Net Income25.20M24.40M15.40M24.90M44.60M41.70M
Balance Sheet
Total Assets327.40M321.90M313.70M311.60M336.10M298.40M
Cash, Cash Equivalents and Short-Term Investments130.00M96.00M59.90M95.30M166.20M143.10M
Total Debt6.40M12.10M15.20M16.90M2.90M1.90M
Total Liabilities65.30M75.20M75.90M72.40M54.50M45.80M
Stockholders Equity262.10M246.70M237.80M239.20M281.60M252.60M
Cash Flow
Free Cash Flow58.60M56.10M-13.40M1.40M42.20M35.50M
Operating Cash Flow60.30M70.20M-3.80M8.50M46.80M38.10M
Investing Cash Flow6.30M-10.80M-9.60M-10.00M-4.30M-3.80M
Financing Cash Flow-2.10M-23.60M-23.10M-70.70M-19.30M-19.60M

Fevertree Drinks Technical Analysis

Technical Analysis Sentiment
Negative
Last Price815.00
Price Trends
50DMA
870.78
Negative
100DMA
885.44
Negative
200DMA
803.31
Positive
Market Momentum
MACD
-9.51
Positive
RSI
38.87
Neutral
STOCH
5.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FEVR, the sentiment is Negative. The current price of 815 is below the 20-day moving average (MA) of 871.19, below the 50-day MA of 870.78, and above the 200-day MA of 803.31, indicating a neutral trend. The MACD of -9.51 indicates Positive momentum. The RSI at 38.87 is Neutral, neither overbought nor oversold. The STOCH value of 5.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:FEVR.

Fevertree Drinks Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
£12.10B15.7928.56%2.25%6.00%42.42%
71
Outperform
£747.59M15.3515.73%2.53%3.97%34.09%
69
Neutral
£1.59B12.919.02%1.54%1.01%11.12%
69
Neutral
$947.19M38.119.97%2.10%-6.03%13.11%
64
Neutral
£413.15M23.6018.67%2.85%3.04%-6.67%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
54
Neutral
£490.62M43.672.40%6.32%-1.80%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:FEVR
Fevertree Drinks
815.00
73.86
9.97%
GB:BAG
AG Barr
669.00
59.16
9.70%
GB:CCH
Coca Cola HBC
3,356.00
674.40
25.15%
GB:NICL
Nichols
1,125.00
145.68
14.88%
GB:PFD
Premier Foods
181.00
-0.42
-0.23%
GB:CCR
C&C Group Plc
136.00
-20.48
-13.09%

Fevertree Drinks Corporate Events

Other
Fever-Tree Director Increases Stake with Share Purchase
Positive
Sep 12, 2025

Fever-Tree announced that Kevin Havelock, the Senior Independent Non-Executive Director, purchased 37,000 ordinary shares in the company at an average price of GBP 8.46 per share on 11 September 2025 via the London Stock Exchange. This transaction signifies a vote of confidence in the company’s future prospects by a key member of its leadership, potentially impacting investor sentiment and market perception positively.

The most recent analyst rating on (GB:FEVR) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Fevertree Drinks stock, see the GB:FEVR Stock Forecast page.

Stock BuybackDividendsShareholder Meetings
Fever-Tree Proposes Share Premium Cancellation to Boost Reserves
Neutral
Sep 11, 2025

Fever-Tree has announced a proposed cancellation of its share premium account to create distributable reserves that could support share buybacks, future dividend payments, and other corporate purposes. The proposal is contingent upon shareholder approval and court confirmation, with the final hearing expected on 11 November 2025. The cancellation will not affect the rights or number of ordinary shares. The General Meeting to discuss this will be held on 17 October 2025.

The most recent analyst rating on (GB:FEVR) stock is a Hold with a £906.00 price target. To see the full list of analyst forecasts on Fevertree Drinks stock, see the GB:FEVR Stock Forecast page.

Business Operations and StrategyStock BuybackFinancial Disclosures
Fevertree Drinks Reports Strategic Progress and Financial Growth in FY25 Interim Results
Positive
Sep 11, 2025

Fevertree Drinks PLC has reported its FY25 interim results, highlighting strategic progress and alignment with full-year expectations. The company has entered a significant partnership with Molson Coors, granting them exclusive rights to sell, distribute, and produce Fever-Tree products in the US, which is progressing well. Product diversification beyond tonic water has been successful, contributing to 45% of the group’s revenues. Despite challenges in the UK market, the company’s off-trade performance remains robust. Financially, the group has seen a 2% revenue growth at constant currency, with a notable increase in cash position due to strong cash flow and Molson Coors’ transaction inflows. The company has extended its share buyback program, reflecting confidence in its earnings quality.

The most recent analyst rating on (GB:FEVR) stock is a Hold with a £906.00 price target. To see the full list of analyst forecasts on Fevertree Drinks stock, see the GB:FEVR Stock Forecast page.

Stock Buyback
Fevertree Drinks Executes Share Buyback Program
Neutral
Sep 10, 2025

Fevertree Drinks PLC has repurchased 46,384 of its ordinary shares at an average price of 783.6275 pence per share as part of its ongoing buyback program. This move, authorized by shareholders, is intended to cancel the purchased shares, potentially impacting the company’s stock value and shareholder equity.

The most recent analyst rating on (GB:FEVR) stock is a Hold with a £906.00 price target. To see the full list of analyst forecasts on Fevertree Drinks stock, see the GB:FEVR Stock Forecast page.

Business Operations and StrategyStock Buyback
Fevertree Drinks Executes Share Buyback to Enhance Shareholder Value
Positive
Sep 9, 2025

Fevertree Drinks PLC announced the repurchase of 89,775 ordinary shares as part of its share buyback program, with the intention to cancel these shares. This move, executed through Investec Bank, reflects the company’s ongoing strategy to enhance shareholder value and optimize its capital structure.

The most recent analyst rating on (GB:FEVR) stock is a Hold with a £906.00 price target. To see the full list of analyst forecasts on Fevertree Drinks stock, see the GB:FEVR Stock Forecast page.

Business Operations and StrategyStock Buyback
Fevertree Drinks PLC Executes Share Buyback to Enhance Shareholder Value
Positive
Sep 8, 2025

Fevertree Drinks PLC announced the repurchase of 87,898 ordinary shares as part of its ongoing buyback program, with the intention to cancel these shares. This move, executed through Investec Bank, reflects the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its stock performance and market perception.

The most recent analyst rating on (GB:FEVR) stock is a Hold with a £906.00 price target. To see the full list of analyst forecasts on Fevertree Drinks stock, see the GB:FEVR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 03, 2025